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ABSTRACT
Glaucoma is a common optic neuropathy that
can lead to irreversible vision loss, and
intraocular pressure (IOP) is the only known
modifiable risk factor. The primary method of
treating glaucoma involves lowering IOP using
medications, laser and/or invasive surgery.
Currently, we rely on in-office measurements
of IOP to assess diurnal variation and to define
successful management of disease. These
measurements only convey a fraction of a
patient’s circadian IOP pattern and may
frequently miss peak IOP levels. There is an
unmet need for a reliable and accurate device
for 24-h IOP monitoring. The 24-h IOP
monitoring devices that are currently available
and in development fall into three main
categories: self-monitoring, temporary
continuous monitoring, and permanent
continuous monitoring. This article is a
systematic review of current and future
technologies for measuring IOP over a 24-h
period.
Keywords: 24-h; Contact lens sensor;
EYECARE (Implandata Ophthalmic Products
GmbH); Glaucoma; Icare tonometer (Icare
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INTRODUCTION
Glaucoma is a leading cause of irreversible
blindness with a global impact that is
estimated to include 60.5 million patients
[1, 2]. To date, intraocular pressure (IOP) is the
only modifiable risk factor. Treatment decisions
are based on in-office measurements of IOP to
assess diurnal variation and to define successful
management of disease; however, these
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measurements only convey a fraction of a
patient’s circadian IOP pattern. It has been
well documented that patients can
demonstrate a wide variability in IOP
throughout a 24-h period due to activity,
nocturnal elevation, physiologic body position
(supine vs. erect), and individual variability of
response to topical medications [3, 4].
Several studies have emphasized the clinical
relevance of 24-h IOP monitoring, which have
revealed that higher peak IOPs and a wider
range of IOP fluctuations correlate with
confirmed progression. In a retrospective
study, 29 patients with primary open angle
glaucoma (POAG) and normal tension
glaucoma (NTG) underwent 24-h IOP
monitoring in a hospital sleep laboratory.
These patients were known to have confirmed
progression based on perimetry despite
‘‘well-controlled’’ IOP measurements during
clinic visits. Their 24-h IOP curve was
compared to their previously measured
clinic-based IOP curve while maintaining their
current glaucoma medication regimen. The
mean IOP value was similar between the two
groups; however, the peak 24-h IOP was
4.9 mmHg higher than the clinic-based diurnal
curve (p\0.0001). In addition, the 24-h IOP
curve for four patients demonstrated at least a
12 mmHg increase in peak IOP. Approximately
51.7% of patients recorded their peak IOP
outside standard office hours, although no
specific aggregate pattern was revealed [5].
Similarly, another retrospective study
reviewed the 24-h IOP curve obtained in a
hospital sleep laboratory for 32 patients with
POAG with known progression. The 24-h IOP
curve demonstrated a wider range (6.9 ± 2.9 vs.
3.8 ± 2.3 mmHg; p\0.001) and a higher peak
IOP for 62% of patients when compared to
office-based measurements [6]. In a prospective
study, 103 patients with newly diagnosed POAG
and pseudoexfoliation glaucoma (PXG)
underwent 24-h IOP monitoring in a hospital
sleep laboratory prior to initiating glaucoma
therapy. Compared to POAG, the PXG patients
demonstrated a wider range of IOP (13.5 vs.
8.5 mmHg; p\0.001), higher peak IOP (38.2 vs.
26.9 mmHg; p\0.001), and higher minimum
IOP (24.7 vs. 18.4 mmHg; p\0.001). In
addition, 45% of PXG and 22.5% of POAG
patients recorded their peak level of IOP outside
standard office hours [7].
At present, hospitalization in a sleep
laboratory for serial measurements is required
to obtain a patient’s 24-h IOP curve, which is
both cumbersome and expensive [8]. In
addition, the gold standard for measuring IOP,
Goldmann applanation tonometry (GAT), can
be influenced by multiple variables that include
pachymetry, keratometry, the amount of
fluorescein in the tear film, Valsalva, eye
position, and interobserver error [9, 10].
In the era of advanced bioinformatics, there is
a need for a more accurate and precise method of
continuous IOP monitoring, which will allow
physicians to better understand the nature of
their patient’s disease process and thus improve
treatment regimens. Devices that are currently
available and in development fall into three
main categories: patient self-monitoring,
temporary continuous monitoring, and
permanent continuous monitoring (Table 1).
This article is a systematic review of current
devices for 24-h IOP monitoring that follows
the principles of the Rapid Evidence Assessment
methodology. It is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
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SELF-MONITORING DEVICES
Many handheld, portable self-monitoring
devices have been proposed and evaluated on
the basis of ease of use, portability, safety
profile, reliability, and accuracy.
The Tono-Pen (Reichert Technologies,
Depew, NY, USA) [11] is a portable device that
relies on the principles of applanation
tonometry to measure IOP. It is reputable for
its strong correlation with Goldmann
applanation at physiologic pressures [12, 13]
and is widely used in a variety of clinical
settings. However, it has not been advocated
for home self-monitoring because it requires the
use of a topical anesthetic, which is associated
with corneal endothelial toxicity [14, 15].
In 1998, it was suggested that IOP has a
direct correlation to the amount of external
pressure that needs to be applied to the ocular
surface to create a visual aura, or phosphene.
On the basis of these observations, the Proview
Eye Pressure Monitor (Bausch and Lomb,
Rochester, NY, USA) was introduced. The
device has a circular tip that is applied to the
eyelid at the superonasal quadrant, and the
patient applies increasing external pressure
until a visual aura is produced and the
corresponding IOP is then recorded. The
device is portable, does not require a topical
anesthetic, and is easy and safe to use.
However, clinical studies have shown a poor
correlation with GAT and Tono-Pen
measurements [14, 16–18].
Dekking and Coster first described the
principle of rebound tonometry (RT) in 1967
[19, 20]. This discovery led to the development
of the iCare tonometer (iCare Finland) [21],
which was introduced in the USA in 2007. It is a
handheld device that consists of a metallic
motion probe with a plastic tip that is poised
in a coil system. The probe accelerates towards
Table 1 Current devices for 24-h IOP monitoring
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the cornea within a magnetic field at a speed of
0.25–0.35 m/s. The tonometer estimates the IOP
based on the deceleration parameters of the
probe as it rebounds from the cornea. Once six
reliable measurements are recorded, the
maximum and minimum values are discarded
before the average IOP is calculated on the basis
of the remaining four measurements [22].
No topical anesthetic is required and the
iCare tonometer has demonstrated a strong
correlation with Goldmann applanation
[22–24]. However, it has been noted that
corneal properties, which include central
corneal thickness (CCT), corneal hysteresis
(CH), and corneal resistance factor (CRF), can
affect the accuracy of IOP measurements
[25, 26]. The iCare tends to overestimate IOP
when compared to GAT in patients with thicker
CCT [22–24] but is more reliable at the
peripheral cornea [27, 28] and is independent
of corneal curvature [29].
In addition, the reliability and accuracy
decline when there is misalignment, which
can be influenced by head position, dexterity,
and eye movement. The traditional iCare model
may be used in the upright or lateral decubitus
position but is unable to measure supine IOP
because of probe displacement when the device
is inverted [14, 16, 22, 30]. The new iCare Pro
has a built-in inclination sensor that allows IOP
measurements in the supine position [31]. The
US model and iCare Pro require the
participation of a separate observer but can be
easily used by non-specialized personnel with
minimal training.
There are two iCare models designed for
self-monitoring that are currently available
outside the USA, namely the iCare Home
(Fig. 1) and its predecessor, the iCare One.
Clinical trials have demonstrated that
self-monitoring IOP measurements taken
by iCare One have a strong correlation to
GAT measurements with patients reporting
subjective ease of use [32–34]. The current
updates to the iCare design increase its
potential for widespread use as a portable IOP
self-monitoring device.
In one study, the concurrent measurements
using the self-monitoring iCare One and
clinician-obtained GAT IOP were compared for
149 patients with ocular hypertension (OHT)
and glaucoma. The iCare One IOP values were
within 3 mmHg of corresponding GAT values
for 67.1% of patients. The differences noted
between the iCare One and GAT were not
significant (p = 0.41) if the dominant hand
was used for self-monitoring. In addition, more
than 77% of participants reported ease of use
with the iCare One [34].
A recent study investigated the accuracy
of self-obtained, partner-obtained, and trainer-
obtained iCare Home IOP measurements
compared to GAT. After a standardized
training regimen, 74% of subjects were able to
successfully use the iCare Home for self-
monitoring. The acceptability questionnaire
revealed that the device was easy to use (84%),
measurements were quick to obtain (88%), and
the device was comfortable (95%). However the
iCare Home was inclined to underestimate the
IOP compared to GAT: self-obtained IOP,
0.3 mmHg (95% CI -4.6 to 5.2 mmHg);
Fig. 1 Icare Home (Icare Finland Oy) self-monitoring
device
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partner-obtained IOP, 1.1 mmHg (95% CI -3.2
to 5.3 mmHg); and trainer-obtained IOP,
1.2 mmHg (95% CI -3.9 to 6.3 mmHg).
Self-obtained iCare Home IOP measurements
demonstrated the least discrepancy with
GAT, although there was a greater difference




In the 1970s, Greene and Gilman proposed the
use of contact lenses for continuous IOP
monitoring. They embedded two strain gauges
in a soft contact lens and measured the changes
in the meridional angle of the cornea–scleral
junction to assess fluctuations in IOP [36].
Given the necessity to custom fit each contact
lens, cost became an insurmountable barrier to
its widespread use [37].
The next attempt followed a few decades
later. Ziemer Ophthalmic Systems introduced a
rigid gas-permeable contact lens (RGP) with a
piezoresistive pressure sensor that was centered
within the lens and seated flush to the posterior
surface. Lead wires, extending from the anterior
surface of the sensor, were attached to a base
unit that would continuously record the
patient’s IOP [38]. Twa et al. demonstrated
that measurements were comparable to
dynamic contour tonometry in the seated
position [39]. However, there were several
drawbacks noted with this model design. The
sensor was placed directly in the visual axis,
thus impeding vision. Patients also reported
subjective discomfort with RGP wear. In
addition, the central processing unit needed to
be supported and carried with caution to
prevent external vector forces that would
influence IOP readings [37, 39].
Since then, the Swiss company Sensimed has
introduced the Triggerfish contact lens sensor
(CLS), which is currently approved in Europe
and has recently been approved by the Food
and Drug Administration in the USA [40]. The
device is based on the principle that small
changes in ocular circumference, measured at
the cornea–scleral junction, correspond to
changes in intraocular pressure and volume, as
well as ocular biomechanical properties. The
underlying assumption is that 1 mmHg in IOP
is equivalent to a 3-lm change in the radius of
curvature of the cornea [37, 41, 42].
The device itself is a soft silicone contact lens
embedded with a circumferential sensor
consisting of two platinum–titanium strain
gauges that measure changes in the radius
of curvature of the cornea (Fig. 2). To ensure
a good fit, there are three different base
curves available. An embedded microprocessor
transmits an output signal to an adhesive
wireless antenna that is secured externally
to the periocular surface. The wireless
antenna recharges the microprocessor and
simultaneously receives continuous data, as
measured in units of electrical voltage. The
data is transferred by a cable wire to a
portable recorder worn at the patients side,
Fig. 2 Triggerﬁsh (Sensimed AG) contact lens sensor
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which allows the patient to be ambulatory. Each
data set consists of 300 data points acquired
during a 30-s interval that occurs every 5 min,
which is equivalent to 288 data sets in 24 h
[37, 41, 42].
In vitro studies have demonstrated that the
Triggerfish CLS produces reliable measurements
of IOP during ocular pulsations and linear
changes of a known control [43]. Clinical trials
have highlighted that transient blurred vision
and hyperemia are the most common patient
complaints; but more importantly, no serious
adverse events have been reported [37, 42]. To
date, the Triggerfish CLS has been used to study
the circadian pattern in healthy individuals, as
well as those with POAG, NTG, PXG [44, 45]
and patients with thyroid eye disease [46].
Use of the CLS has provided new insights
into the effects of selective laser trabeculoplasty
(SLT). In a prospective study, 18 NTG patients
underwent SLT. Their baseline and 1-month
24-h IOP curves were obtained with the
Triggerfish CLS for comparison. Patients with
successful treatment, as defined by an IOP
reduction of at least 20% by GAT, displayed a
24.6% reduction of mean global variability at
1 month. There was no change in signal
variability noted in the success group, whereas
the patients that failed treatment demonstrated
an increase in diurnal variability [47]. A similar
study compared the baseline, 1-month, and
2-month CLS 24-h IOP curves for 10 patients
with NTG who underwent SLT. In patients that
were successfully treated, the range of IOP
fluctuations during the diurnal period
remained unchanged while the fluctuations
during the nocturnal period decreased from
290 ± 86 mV Eq to 199 ± 31 mV Eq after
treatment (p = 0.014) [48].
In regards to topical medications, the
Triggerfish CLS has struggled to demonstrate
significant changes in the 24-h IOP curve
after treatment when compared to baseline
readings. Mansouri et al. captured the CLS
24-h IOP patterns in 23 patients with POAG
before and after 1-month treatment with one
of four glaucoma medication drug classes.
Prostaglandin analogues revealed flattening of
the nocturnal IOP rise that accompanies the
transition from upright to supine but did not
exhibit an affect on the acrophase or signal
amplitude. All other medication classes failed to
demonstrate an effect on the circadian 24-h IOP
patterns [49]. In another study, nine patients
with OHT and POAG underwent a 6-week
medication washout. Three baseline 24-h IOP
curves were taken including two CLS and one
GAT curve. The patients were placed on
travoprost monotherapy for 3 months before
three additional 24-h IOP curves were obtained.
The 24-h GAT IOP curve decreased from
22.91 ± 5.11 mmHg to 18.24 ± 2.49 mmHg
(p\0.001) after treatment. In contrast, the
CLS curves showed no significant difference
(mean value p = 0.273, SD p = 0.497). All CLS
24-h IOP curves demonstrated a trend for
time-dependent increase with continued wear,
and no IOP changes related to postural changes
(supine vs. erect) were identified [50].
More recently, 24-h IOP profiles obtained
with the Triggerfish CLS have been associated
with the rate of visual field progression in
glaucoma patients. In this prospective,
open-label study, 34 patients with POAG were
divided into two equal groups of fast and slow
progressors on the basis of previous perimetric
trends from eight or more visual fields
administered over 2 years. Each patient
obtained a 24-h CLS IOP curve. For each
additional awake large peak, the rate of
progression based on the mean deviation (MD)
slopes accelerated by -0.14 dB/year, each 10
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unit increase in sleeping mean peak ratio was
associated with an acceleration of -0.20 dB/
year, and for every 10-unit increase in mean
peak ratio while awake the accelerated rate of
progression was -0.07 dB/year [51]. This
suggests that the main utility of the CLS data
may come from the 24-h IOP profile and ability
to detect short- and long-term IOP fluctuations
as a result of medications, activity, and body
position.
Currently, the Triggerfish CLS is the only
commercially available device for temporary
continuous 24-h IOP monitoring [40]. It is
non-invasive and has a low risk profile. One
major advantage of the CLS is that patients can
be ambulatory during the measurements, rather
than being housed in a 24-h sleep laboratory,
therefore providing a more accurate individual
IOP profile that reflects a patient’s typical daily
routine. The amount of data received per
patient is abundant and has the potential to
provide new insights as to how eye position,
blinks, topical medications, laser and surgical
interventions, as well as lifestyle can affect a
patient’s circadian IOP pattern.
With every technological advancement there
are new challenges to overcome. One major
obstacle encountered with the Triggerfish CLS is
that the data is recorded in millivolt equivalents
rather than millimeters of mercury. The
conversion of millivolt equivalents to
millimeters of mercury is complex because the
relationship between volume and pressure is
non-linear and is influenced by the viscoelastic
properties of the eye. New algorithms need to be
developed to translate the data and validate its
correlation to our current standards for IOP
measurement. In addition, cost of the device
may become an obstacle to more widespread
use [16, 37, 52].
PERMANENT CONTINUOUS
MONITORING DEVICES
A German company has introduced an
implantable intraocular device that is
currently being vetted through human clinical
trials. The Implandata EyeMate is a wireless
intraocular transducer (WIT) that consists of
eight pressure and temperature sensors, an
identification and analog-to-digital encoder, as
well as a telemetry unit. The electronic
components are attached to a gold circular
antenna and the entire device is encapsulated
in platinum-cured silicone. Each component is
either inert or biocompatible. The outside
diameter is 11.3 mm, with an inside diameter
of 7 mm, thickness of 0.9 mm, and weighs 0.1 g.
The design is compatible with ciliary sulcus
placement. Although the electronic component
is rigid, the remainder of the device is malleable
and can be folded for intraocular implantation
[53, 54].
Each pressure sensor is composed of two
parallel plates, a thin flexible plate that indents
with changes in IOP and a thicker rigid base
plate. As the distance between the two plates
varies with changes in IOP, a corresponding
analog signal is generated. This analog signal is
converted to a digital signal that is transmitted
externally by radiofrequency. A handheld
reader unit receives the digital data and
visually displays the IOP value. The reader
and the intraocular transponder unit must be
within 5 cm of each other before the reader can
activate the electromagnetic coupling sequence
and the two units can correspond with each
other. The device can obtain up to ten IOP
measurements per second and there are a range
of settings that allow for monitoring at variable
intervals [53, 54].
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The handheld reader also charges the WIT
externally through electromagnetic inductive
coupling. The base unit can store up to 3000
IOP measurements and additional memory
modules can be added to the reader device. An
optional wireless module can be installed to
automatically download all measured data to a
cloud-based server, allowing the clinical
provider easy and instantaneous access to the
data [53, 54].
In vitro studies have demonstrated the
lasting durability of the EyeMate as a wireless
IOP transducer. According to Implandata, their
WIT device was soaked in saline for 4 years and
continued to remain functional, thus
establishing its potential for endurance in
aqueous solution. In addition, six devices
were immersed in saline for 515 days and
were subjected to an absolute test pressure
of 1000 hPa (sea level) at 36 C. The
average drift in intraocular pressure was
3.47 mmHg compared to the calculated drift
rate of 2.46 mmHg, confirming that the
measurements taken maintained a practical
precision when tested under simulated
physiologic conditions [55]. In vitro studies
have demonstrated that the Implandata
EyeMate is biocompatible with good subjective
tolerance in rabbit eyes for up to 25 months.
This was confirmed by the lack of intraocular
toxicity on histopathology [55, 56].
In the ARGOS-O1 study, six patients with
well-controlled POAG or NTG and visually
significant cataracts underwent an uneventful
cataract surgery and sulcus placement of
the Implandata EyeMate (Fig. 3), which
was confirmed by ultrasound biomicroscopy.
Four patients demonstrated a significant
postoperative inflammatory response that
lasted up to 9 days and was successfully
treated with topical and oral steroids. At 1 year
postoperatively, all patients maintained control
of their glaucoma and there was no incidence of
pupillary block, angle closure, corneal edema,
retinal detachment, endophthalmitis, bleeding,
macular edema, or visual deterioration. The
endothelial cell count and central corneal
thickness remained stable in all patients [57].
Although the telemetric intraocular pressure
curves for all patients were comparable to the
circadian pattern outlined by consecutive IOP
measurements by GAT, three patients had a
significant positive shift in their telemetric IOP
curves after 5–6 months and one patient
consistently had a negative telemetric IOP
curve despite stable GAT readings. The sensor’s
unpredictable variance leads to issues
concerning the interpretation and clinical
application of the WIT telemetric curves.
Consecutive GAT measurements are likely to
be necessary as a benchmark for comparison
until we are able to formulate guidelines
for interpretation based on additional
evidence-based research [57].
Currently, there is an open enrollment for a
prospective, multicenter clinical trial to assess
the safety and efficacy of the device for patients
Fig. 3 ARGOS intraocular pressure sensor. Republished
with permission of the Association for Research in Vision
and Ophthalmology from Koutsonas et al. [57]; permission
conveyed through Copyright Clearance Center, Inc.
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with POAG [58]. The device is promising and
clinicians are eagerly awaiting further clinical
data before the Implandata EyeMate will
become commercially available for patient care.
Meanwhile, several other companies are also
working to develop a biocompatible and
effective wireless intraocular IOP sensor.
AcuMEMS (Menlo Park, CA, USA) has
developed an implantable sensor technology,
called the iSense System. The company is
currently testing two different devices, one
that can be placed in the anterior chamber as
a stand-alone procedure and one that can be
placed in the capsular bag in conjunction with
cataract surgery. Both have shown initial
success in animal trials [59]. LaunchPoint
Technologies (Goleta, CA) is currently
developing an intraocular sensor that can be
attached directly to an intraocular lens or
injected into the vitreous cavity [60, 61]. All of
these intraocular sensors are considered
‘‘passive’’ wireless devices that are dependent
on the proximity of an external reader to charge
the internal unit and extract data. Solx
(Waltham, MA) is pursuing an ‘‘active’’ wireless
intraocular sensor that will be independent of
an external reader [62, 63].
CONCLUSION
With the advent of new technologies and a
growing emphasis on bioinformatics, customized
treatment regimens will become the standard of
care for glaucoma. A reliable, accurate, mobile
24-h IOP monitoring device will provide a novel
understanding of a patient’s individual IOP
circadian pattern. It may allow for a paradigm
shift in the way we interpret and treat glaucoma.
However, with each innovation there are new
challenges that include novel methods of data
collection, portability, tolerance with long-term
use, and the cost per device. With time, these
challenges will be addressed and our patients will
be offered a variety of options for 24-h IOP
monitoring.
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